Urinary and genital infections in patients with diabetes: How to diagnose and how to treat
Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decr...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Njomnang Soh, P. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Serological and molecular evaluation of - Uy, Mary Rose D. ELSEVIER, 2018, Issy-les-Moulineaux |
|---|---|
| Übergeordnetes Werk: |
volume:42 ; year:2016 ; number:1 ; pages:16-24 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.diabet.2015.07.002 |
|---|
| Katalog-ID: |
ELV019690401 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV019690401 | ||
| 003 | DE-627 | ||
| 005 | 20230625130455.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diabet.2015.07.002 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016019000006.pica |
| 035 | |a (DE-627)ELV019690401 | ||
| 035 | |a (ELSEVIER)S1262-3636(15)00093-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |a 570 |q VZ |
| 084 | |a 44.43 |2 bkl | ||
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Njomnang Soh, P. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Urinary and genital infections in patients with diabetes: How to diagnose and how to treat |
| 264 | 1 | |c 2016transfer abstract | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. | ||
| 520 | |a Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. | ||
| 650 | 7 | |a Genital infections |2 Elsevier | |
| 650 | 7 | |a Urinary infections |2 Elsevier | |
| 650 | 7 | |a Diabetes |2 Elsevier | |
| 650 | 7 | |a Review |2 Elsevier | |
| 650 | 7 | |a SGLT2 inhibitors |2 Elsevier | |
| 700 | 1 | |a Vidal, F. |4 oth | |
| 700 | 1 | |a Huyghe, E. |4 oth | |
| 700 | 1 | |a Gourdy, P. |4 oth | |
| 700 | 1 | |a Halimi, J.M. |4 oth | |
| 700 | 1 | |a Bouhanick, B. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Masson |a Uy, Mary Rose D. ELSEVIER |t Serological and molecular evaluation of |d 2018 |g Issy-les-Moulineaux |w (DE-627)ELV001177605 |
| 773 | 1 | 8 | |g volume:42 |g year:2016 |g number:1 |g pages:16-24 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.diabet.2015.07.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.43 |j Medizinische Mikrobiologie |q VZ |
| 936 | b | k | |a 44.75 |j Infektionskrankheiten |j parasitäre Krankheiten |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 42 |j 2016 |e 1 |h 16-24 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s p n sp spn |
|---|---|
| matchkey_str |
njomnangsohpvidalfhuygheegourdyphalimijm:2016----:rnradeiaifciniptetwtdaeehwo |
| hierarchy_sort_str |
2016transfer abstract |
| bklnumber |
44.43 44.75 |
| publishDate |
2016 |
| allfields |
10.1016/j.diabet.2015.07.002 doi GBVA2016019000006.pica (DE-627)ELV019690401 (ELSEVIER)S1262-3636(15)00093-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Njomnang Soh, P. verfasserin aut Urinary and genital infections in patients with diabetes: How to diagnose and how to treat 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors Elsevier Vidal, F. oth Huyghe, E. oth Gourdy, P. oth Halimi, J.M. oth Bouhanick, B. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:1 pages:16-24 extent:9 https://doi.org/10.1016/j.diabet.2015.07.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 1 16-24 9 045F 610 |
| spelling |
10.1016/j.diabet.2015.07.002 doi GBVA2016019000006.pica (DE-627)ELV019690401 (ELSEVIER)S1262-3636(15)00093-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Njomnang Soh, P. verfasserin aut Urinary and genital infections in patients with diabetes: How to diagnose and how to treat 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors Elsevier Vidal, F. oth Huyghe, E. oth Gourdy, P. oth Halimi, J.M. oth Bouhanick, B. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:1 pages:16-24 extent:9 https://doi.org/10.1016/j.diabet.2015.07.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 1 16-24 9 045F 610 |
| allfields_unstemmed |
10.1016/j.diabet.2015.07.002 doi GBVA2016019000006.pica (DE-627)ELV019690401 (ELSEVIER)S1262-3636(15)00093-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Njomnang Soh, P. verfasserin aut Urinary and genital infections in patients with diabetes: How to diagnose and how to treat 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors Elsevier Vidal, F. oth Huyghe, E. oth Gourdy, P. oth Halimi, J.M. oth Bouhanick, B. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:1 pages:16-24 extent:9 https://doi.org/10.1016/j.diabet.2015.07.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 1 16-24 9 045F 610 |
| allfieldsGer |
10.1016/j.diabet.2015.07.002 doi GBVA2016019000006.pica (DE-627)ELV019690401 (ELSEVIER)S1262-3636(15)00093-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Njomnang Soh, P. verfasserin aut Urinary and genital infections in patients with diabetes: How to diagnose and how to treat 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors Elsevier Vidal, F. oth Huyghe, E. oth Gourdy, P. oth Halimi, J.M. oth Bouhanick, B. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:1 pages:16-24 extent:9 https://doi.org/10.1016/j.diabet.2015.07.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 1 16-24 9 045F 610 |
| allfieldsSound |
10.1016/j.diabet.2015.07.002 doi GBVA2016019000006.pica (DE-627)ELV019690401 (ELSEVIER)S1262-3636(15)00093-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Njomnang Soh, P. verfasserin aut Urinary and genital infections in patients with diabetes: How to diagnose and how to treat 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors Elsevier Vidal, F. oth Huyghe, E. oth Gourdy, P. oth Halimi, J.M. oth Bouhanick, B. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:1 pages:16-24 extent:9 https://doi.org/10.1016/j.diabet.2015.07.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 1 16-24 9 045F 610 |
| language |
English |
| source |
Enthalten in Serological and molecular evaluation of Issy-les-Moulineaux volume:42 year:2016 number:1 pages:16-24 extent:9 |
| sourceStr |
Enthalten in Serological and molecular evaluation of Issy-les-Moulineaux volume:42 year:2016 number:1 pages:16-24 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Medizinische Mikrobiologie Infektionskrankheiten parasitäre Krankheiten |
| institution |
findex.gbv.de |
| topic_facet |
Genital infections Urinary infections Diabetes Review SGLT2 inhibitors |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Serological and molecular evaluation of |
| authorswithroles_txt_mv |
Njomnang Soh, P. @@aut@@ Vidal, F. @@oth@@ Huyghe, E. @@oth@@ Gourdy, P. @@oth@@ Halimi, J.M. @@oth@@ Bouhanick, B. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV001177605 |
| dewey-sort |
3610 |
| id |
ELV019690401 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV019690401</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625130455.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diabet.2015.07.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016019000006.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV019690401</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1262-3636(15)00093-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.43</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Njomnang Soh, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urinary and genital infections in patients with diabetes: How to diagnose and how to treat</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Genital infections</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Urinary infections</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Diabetes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Review</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SGLT2 inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vidal, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huyghe, E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gourdy, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Halimi, J.M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bouhanick, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Masson</subfield><subfield code="a">Uy, Mary Rose D. ELSEVIER</subfield><subfield code="t">Serological and molecular evaluation of</subfield><subfield code="d">2018</subfield><subfield code="g">Issy-les-Moulineaux</subfield><subfield code="w">(DE-627)ELV001177605</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:42</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:16-24</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diabet.2015.07.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.43</subfield><subfield code="j">Medizinische Mikrobiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.75</subfield><subfield code="j">Infektionskrankheiten</subfield><subfield code="j">parasitäre Krankheiten</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">42</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">16-24</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Njomnang Soh, P. |
| spellingShingle |
Njomnang Soh, P. ddc 610 bkl 44.43 bkl 44.75 Elsevier Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors Urinary and genital infections in patients with diabetes: How to diagnose and how to treat |
| authorStr |
Njomnang Soh, P. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV001177605 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Urinary and genital infections in patients with diabetes: How to diagnose and how to treat Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors Elsevier |
| topic |
ddc 610 bkl 44.43 bkl 44.75 Elsevier Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors |
| topic_unstemmed |
ddc 610 bkl 44.43 bkl 44.75 Elsevier Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors |
| topic_browse |
ddc 610 bkl 44.43 bkl 44.75 Elsevier Genital infections Elsevier Urinary infections Elsevier Diabetes Elsevier Review Elsevier SGLT2 inhibitors |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
f v fv e h eh p g pg j h jh b b bb |
| hierarchy_parent_title |
Serological and molecular evaluation of |
| hierarchy_parent_id |
ELV001177605 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology |
| hierarchy_top_title |
Serological and molecular evaluation of |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV001177605 |
| title |
Urinary and genital infections in patients with diabetes: How to diagnose and how to treat |
| ctrlnum |
(DE-627)ELV019690401 (ELSEVIER)S1262-3636(15)00093-2 |
| title_full |
Urinary and genital infections in patients with diabetes: How to diagnose and how to treat |
| author_sort |
Njomnang Soh, P. |
| journal |
Serological and molecular evaluation of |
| journalStr |
Serological and molecular evaluation of |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
16 |
| author_browse |
Njomnang Soh, P. |
| container_volume |
42 |
| physical |
9 |
| class |
610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Njomnang Soh, P. |
| doi_str_mv |
10.1016/j.diabet.2015.07.002 |
| dewey-full |
610 570 |
| title_sort |
urinary and genital infections in patients with diabetes: how to diagnose and how to treat |
| title_auth |
Urinary and genital infections in patients with diabetes: How to diagnose and how to treat |
| abstract |
Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. |
| abstractGer |
Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. |
| abstract_unstemmed |
Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Urinary and genital infections in patients with diabetes: How to diagnose and how to treat |
| url |
https://doi.org/10.1016/j.diabet.2015.07.002 |
| remote_bool |
true |
| author2 |
Vidal, F. Huyghe, E. Gourdy, P. Halimi, J.M. Bouhanick, B. |
| author2Str |
Vidal, F. Huyghe, E. Gourdy, P. Halimi, J.M. Bouhanick, B. |
| ppnlink |
ELV001177605 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.diabet.2015.07.002 |
| up_date |
2024-07-06T22:06:28.728Z |
| _version_ |
1803869055855099904 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV019690401</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625130455.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diabet.2015.07.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016019000006.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV019690401</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1262-3636(15)00093-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.43</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Njomnang Soh, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urinary and genital infections in patients with diabetes: How to diagnose and how to treat</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Diabetes is a predisposing factor for urinary tract and genital infections in both women and men. Sodium–glucose cotransporter-2 (SGLT2) inhibitors constitute a novel therapeutic class indicated for type 2 diabetes (T2D) patients, and are already on the market in a few countries in Europe. They decrease glycaemia mainly by enhancing glucose excretion in urine by reducing renal glucose reabsorption via the action of SGLT2 in the kidneys. In general, they are well tolerated, but their mode of action results in specific side effects as well as an increased risk of genital (vulvovaginitis and balanitis) and urinary tract infections, for which T2D patients are already at high risk, reported within the first 6 months of treatment. Usually these infectious events are successfully treated with standard therapies, but diabetologists are not accustomed to dealing with them. The aim of this review is to describe the different types of lower urinary tract and genital infections, and the treatment strategies currently available for patients with diabetes.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Genital infections</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Urinary infections</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Diabetes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Review</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">SGLT2 inhibitors</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vidal, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huyghe, E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gourdy, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Halimi, J.M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bouhanick, B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Masson</subfield><subfield code="a">Uy, Mary Rose D. ELSEVIER</subfield><subfield code="t">Serological and molecular evaluation of</subfield><subfield code="d">2018</subfield><subfield code="g">Issy-les-Moulineaux</subfield><subfield code="w">(DE-627)ELV001177605</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:42</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:16-24</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diabet.2015.07.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.43</subfield><subfield code="j">Medizinische Mikrobiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.75</subfield><subfield code="j">Infektionskrankheiten</subfield><subfield code="j">parasitäre Krankheiten</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">42</subfield><subfield code="j">2016</subfield><subfield code="e">1</subfield><subfield code="h">16-24</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401101 |